

Global BREO Ellipta Drugs Market Report and Forecast 2023-2031

Market Report | 2023-03-22 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global BREO Ellipta Drugs Market Report and Forecast 2023-2031

Global BREO Ellipta Drugs Market Outlook

The global BREO ellipta drugs market is driven by the growing chronic obstructive pulmonary disease drugs market, which is likely to grow at a rate of 4.50% during the forecast period of 2023-2031. The prevalence of these respiratory disease is expected to rise significantly over the coming years due to rising pollution levels, along with other factors.

Introduction to the BREO Ellipta Drugs Market

BREO Ellipta is a combination drug that contains fluticasone furoate, an inhaled corticosteroid, and vilanterol, a long-acting beta2-adrenergic agonist. The drug is used to treat asthma and chronic obstructive pulmonary disease (COPD) by reducing inflammation in the airways and relaxing the muscles around the airways to improve breathing. The increasing prevalence of respiratory disorders, such as asthma and COPD, is driving the demand for BREO Ellipta drugs. Factors such as aging population, increasing air pollution, and rising awareness about the importance of effective treatment for respiratory disorders are also expected to drive market growth.

Advancements in technology and drug delivery systems have played a significant role in the growth of the BREO Ellipta drugs market. The development of inhalers with improved drug delivery and reduced side effects has expanded the reach of BREO Ellipta drugs and helped to meet the growing demand for these medications.

The BREO Ellipta drugs market is expected to continue to grow in the coming years, as awareness of the importance of effective treatment for respiratory disorders increases, and new treatment options and technologies are developed to meet the needs of patients with asthma and COPD. However, there are still significant barriers to accessing BREO Ellipta drugs, particularly in low- and middle-income countries, where access to healthcare services is often limited. Efforts are underway to address these barriers and improve access to BREO Ellipta drugs globally.

Global BREO Ellipta Drugs Market- Applications

BREO Ellipta drugs market has significant applications in the treatment and management of respiratory disorders, primarily chronic obstructive pulmonary disease (COPD) and asthma. The drug's ability to reduce inflammation and relax the muscles in the airways has made it a popular choice for patients and healthcare providers worldwide.

As the prevalence of these respiratory disorders continues to rise, driven by factors such as aging population, urbanization, and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

increasing air pollution, the demand for effective treatment options like BREO Ellipta is expected to grow. This growth will likely be supported by technological advancements, improved drug delivery systems, and increased awareness of respiratory disorders and their treatments. However, challenges remain in terms of accessibility, especially in low- and middle-income countries, where healthcare infrastructure and resources may be limited.

Overall, the global BREO Ellipta drugs market is poised for continued growth in the coming years, driven by its essential applications in the management of COPD and asthma and the increasing need for innovative and effective treatments for these respiratory conditions.

BREO Ellipta Drugs Market Segmentations

The market can be segmented based on indication type, mode of administration, distribution channel, and region:

Market Breakup by Indication Type

- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Chronic Bronchitis
- Asthma
- Others

Market Breakup by Mode of Administration

- Dry Powder Inhaler
- Respimat Soft Mist Inhaler
- Pressurized Metered Dose Inhaler
- Nebulizers
- Others

Market Breakup by Distribution Channel

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

Market Breakup by Region

- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

BREO Ellipta Drugs Market Analysis

The global BREO Ellipta drugs market is expected to experience significant growth over the forecast period, driven by factors such as the increasing prevalence of asthma and COPD, and the rising demand for effective and innovative treatments for these respiratory disorders.

The North America region is currently the largest market for BREO Ellipta drugs, dominating the market with a significant share. The region's large market share is driven by factors such as a high prevalence of respiratory disorders, well-established healthcare infrastructure, and strong investment in research and development. In addition, the growing adoption of BREO Ellipta drugs is further driving the growth of the market in North America. Europe is also a significant market for BREO Ellipta drugs, with countries such as Germany, France, and the UK leading the way. The region's market growth is driven by factors such as a large population base, increasing prevalence of respiratory disorders, and the availability of BREO Ellipta drugs through various distribution channels.

The Asia Pacific region is another region that is experiencing significant growth in the BREO Ellipta drugs market. The region's market growth is driven by factors such as a large population base, increasing awareness about respiratory disorders, and the growing adoption of BREO Ellipta drugs. In addition, government initiatives to address respiratory disorders are helping to drive the growth of the market in the region.

Key Suppliers in the Global BREO Ellipta Drugs Market

The report provides a detailed analysis of the key suppliers involved in the BREO Ellipta drugs market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:

- GSK plc
- Akros Pharma Inc
- Sun Pharmaceutical Industries Ltd
- Gilead Sciences, Inc.
- Abbott
- Genosco Inc.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.1.1 Research Objectives
 - 1.1.2 Key Findings of the Report
 - 1.2 Limitations of the Study and Scope for Future Research
- 2 Research Methodology
- 3 Executive Summary
- 4 Global Breo Ellipta Drugs Overview
 - 4.1 Drug Overview
 - 4.1.1 Pharmacodynamics
 - 4.1.2 Pharmacokinetics
 - 4.1.3 Adverse Events
- 5 Patient Profile
 - 5.1 Patient Profile Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2 Patient Psychology and Emotional Impact Factors
- 5.3 Risk Assessment and Treatment Success Rate
- 6 Global Breo Ellipta Drugs Market
 - 6.1 Global Breo Ellipta Drugs Market Overview
 - 6.2 Global Breo Ellipta Drugs Market Analysis
 - 6.2.1 Market Overview
 - 6.2.1.1 Global Breo Ellipta Drugs Market Historical Value (2016-2022)
 - 6.2.1.2 Global Breo Ellipta Drugs Market Forecast Value (2023-2031)
 - 6.3 Global Breo Ellipta Drugs Market by Indication Type
 - 6.3.1 Market Overview
 - 6.3.1.1 Chronic Obstructive Pulmonary Disease (COPD)
 - 6.3.1.2 Cystic Fibrosis
 - 6.3.1.3 Chronic Bronchitis
 - 6.3.1.4 Asthma
 - 6.3.1.5 Others
 - 6.4 Global Breo Ellipta Drugs Market by Mode of Administration
 - 6.4.1 Market Overview
 - 6.4.1.1 Dry Powder Inhaler
 - 6.4.1.2 Respimat Soft Mist Inhaler
 - 6.4.1.3 Pressurized Metered Dose Inhaler
 - 6.4.1.4 Nebulizers
 - 6.4.1.5 Others
 - 6.5 Global Breo Ellipta Drugs Market by Distribution Channel
 - 6.5.1 Market Overview
 - 6.5.1.1 Hospital Based Pharmacies
 - 6.5.1.2 Online Pharmacies
 - 6.5.1.3 Retail Pharmacies
 - 6.6 Global Breo Ellipta Drugs Market by Region
 - 6.6.1 Market Overview
 - 6.6.1.1 North America
 - 6.6.1.1.1 Historical Trend (2016-2022)
 - 6.6.1.1.2 Forecast Trend (2023-2031)
 - 6.6.1.2 Europe
 - 6.6.1.2.1 Historical Trend (2016-2022)
 - 6.6.1.2.2 Forecast Trend (2023-2031)
 - 6.6.1.3 Asia Pacific
 - 6.6.1.3.1 Historical Trend (2016-2022)
 - 6.6.1.3.2 Forecast Trend (2023-2031)
 - 6.6.1.4 Latin America
 - 6.6.1.4.1 Historical Trend (2016-2022)
 - 6.6.1.4.2 Forecast Trend (2023-2031)
 - 6.6.1.5 Middle East and Africa
 - 6.6.1.5.1 Historical Trend (2016-2022)
 - 6.6.1.5.2 Forecast Trend (2023-2031)
 - 7 North America Breo Ellipta Drugs Market
 - 7.1 United States of America
 - 7.1.1 Historical Trend (2016-2022)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.1.2 Forecast Trend (2023-2031)
- 7.2 Canada
 - 7.2.1 Historical Trend (2016-2022)
 - 7.2.2 Forecast Trend (2023-2031)
- 8 Europe Breo Ellipta Drugs Market
 - 8.1 United Kingdom
 - 8.1.1 Historical Trend (2016-2022)
 - 8.1.2 Forecast Trend (2023-2031)
 - 8.2 Germany
 - 8.2.1 Historical Trend (2016-2022)
 - 8.2.2 Forecast Trend (2023-2031)
 - 8.3 France
 - 8.3.1 Historical Trend (2016-2022)
 - 8.3.2 Forecast Trend (2023-2031)
 - 8.4 Italy
 - 8.4.1 Historical Trend (2016-2022)
 - 8.4.2 Forecast Trend (2023-2031)
- 9 Asia Pacific Breo Ellipta Drugs Market
 - 9.1 China
 - 9.1.1 Historical Trend (2016-2022)
 - 9.1.2 Forecast Trend (2023-2031)
 - 9.2 Japan
 - 9.2.1 Historical Trend (2016-2022)
 - 9.2.2 Forecast Trend (2023-2031)
 - 9.3 India
 - 9.3.1 Historical Trend (2016-2022)
 - 9.3.2 Forecast Trend (2023-2031)
 - 9.4 ASEAN
 - 9.4.1 Historical Trend (2016-2022)
 - 9.4.2 Forecast Trend (2023-2031)
 - 9.5 Australia
 - 9.5.1 Historical Trend (2016-2022)
 - 9.5.2 Forecast Trend (2023-2031)
- 10 Latin America Breo Ellipta Drugs Market
 - 10.1 Brazil
 - 10.1.1 Historical Trend (2016-2022)
 - 10.1.2 Forecast Trend (2023-2031)
 - 10.2 Argentina
 - 10.2.1 Historical Trend (2016-2022)
 - 10.2.2 Forecast Trend (2023-2031)
 - 10.3 Mexico
 - 10.3.1 Historical Trend (2016-2022)
 - 10.3.2 Forecast Trend (2023-2031)
- 11 Middle East and Africa Breo Ellipta Drugs Market
 - 11.1 Saudi Arabia
 - 11.1.1 Historical Trend (2016-2022)
 - 11.1.2 Forecast Trend (2023-2031)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.2 United Arab Emirates
 - 11.2.1 Historical Trend (2016-2022)
 - 11.2.2 Forecast Trend (2023-2031)
- 11.3 Nigeria
 - 11.3.1 Historical Trend (2016-2022)
 - 11.3.2 Forecast Trend (2023-2031)
- 11.4 South Africa
 - 11.4.1 Historical Trend (2016-2022)
 - 11.4.2 Forecast Trend (2023-2031)
- 12 Current Scenario Evaluation and Regulatory Framework
 - 12.1 Emerging Therapies and Clinical Trials Synopsis
 - 12.2 Patent Landscape
 - 12.2.1 Patent Overview
 - 12.2.1.1 Patent Status and Expiry
 - 12.2.1.2 Timelines from Drug Development to Commercial Launch
 - 12.2.1.3 New Drug Application
 - 12.2.1.3.1 Documentation and Approval Process
 - 12.3 Cost of Treatment
 - 12.4 Regulatory Framework
 - 12.4.1 Regulatory Overview
 - 12.4.1.1 US FDA
 - 12.4.1.2 EU EMA
 - 12.4.1.3 INDIA CDSCO
 - 12.4.1.4 JAPAN PMDA
 - 12.4.1.5 Others
- 13 Challenges & Unmet Needs
 - 13.1 Treatment Pathway Challenges
 - 13.2 Compliance and Drop-Out Analysis
 - 13.3 Awareness and Prevention Gaps
- 14 Global Breo Ellipta Drugs Market Dynamics
 - 14.1 Market Drivers and Constraints
 - 14.2 Drug Adoption Parameters
 - 14.3 SWOT Analysis
 - 14.4 Porter Five Forces Model
 - 14.5 Key Demand Indicators
 - 14.6 Key Price Indicators
 - 14.7 Industry Events, Initiatives, and Trends
 - 14.8 Value Chain Analysis
- 15 Supplier Landscape
 - 15.1 GSK plc
 - 15.1.1 Company Overview
 - 15.1.2 Product Portfolio
 - 15.1.3 Demographic Reach and Achievements
 - 15.1.4 Mergers and Acquisitions
 - 15.1.5 Certifications
 - 15.2 Akros Pharma Inc
 - 15.2.1 Company Overview

- 15.2.2 Product Portfolio
- 15.2.3 Demographic Reach and Achievements
- 15.2.4 Mergers and Acquisitions
- 15.2.5 Certifications
- 15.3 Sun Pharmaceutical Industries Ltd
- 15.3.1 Company Overview
- 15.3.2 Product Portfolio
- 15.3.3 Demographic Reach and Achievements
- 15.3.4 Mergers and Acquisitions
- 15.3.5 Certifications
- 15.4 Gilead Sciences, Inc.
- 15.4.1 Company Overview
- 15.4.2 Product Portfolio
- 15.4.3 Demographic Reach and Achievements
- 15.4.4 Mergers and Acquisitions
- 15.4.5 Certifications
- 15.5 Abbott
- 15.5.1 Company Overview
- 15.5.2 Product Portfolio
- 15.5.3 Demographic Reach and Achievements
- 15.5.4 Mergers and Acquisitions
- 15.5.5 Certifications
- 15.6 Genosco Inc.
- 15.6.1 Company Overview
- 15.6.2 Product Portfolio
- 15.6.3 Demographic Reach and Achievements
- 15.6.4 Mergers and Acquisitions
- 15.6.5 Certifications
- 16 Recommendations and Discussion
- 17 Pricing Models and Strategies (Additional Insight)
- 17.1 Cost Model
- 17.1.1 Manufacturing Cost Analysis
- 17.1.2 Procurement Cost Analysis
- 17.2 Pricing Strategies
- 17.2.1 Competitor Pricing Analysis
- 17.2.2 Key Assessment of Product Attributes
- 17.2.3 Pricing Benchmark
- 18 Global Breo Ellipta Drugs Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment

Global BREO Ellipta Drugs Market Report and Forecast 2023-2031

Market Report | 2023-03-22 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-07"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com